Heramed’s DIY fetal ultrasound trial results generate market interest
Heramed (ASX:HMD) runs successful DIY at-home ultrasound trial with Middle East's largest clinic
Source: Unsplash
Mentioned
KEY POINTS
- Digital healthcare player Heramed reports expectant mothers satisfied with telehealth DIY ultrasound service
- Study focused on low-risk pregnant mothers consenting to be part of trial
- Share price has seen a modest boost through to early afternoon trade
Heramed Limited (ASX:HMD) reports its recently concluded DIY telehealth ultrasound trial has been a success.
Conducted in Israel with the Sheba Medical Center, a cohort of pregnant women enrolled to participate in the telehealth service trial.
That trial saw mothers receive online video consultation with doctors, while completing their own fetal ultrasounds with Herameds’ handheld devices.
What are the results?
Worth noting is that overall satisfaction with the trial, self-reported by participants, is ranked as ‘high.’
This suggests low-risk expectant mothers are at ease with Heramed’s DIY ultrasound tech and a large addressable market may well exist.
In another big plus for the company’s technicians, the ultrasound scans were found to provide accurate data on fetal health.
Ultrasound data collected during remote consultation was remotely reviewed by Heramed, and Sheba Center director of Women’s Health Dr. Avi Tsur.
Adding to the profile of today's results: the Sheba Medical Center is the largest in the Middle East.
Heramed's three month charts compared to the healthcare index
